Personalized messenger RNA vaccine first tested in a clinical trial in humans. It improves the immune response and delays relapses.
Results of the phase 1 clinical trial are published in the journal Nature. The study shows that personalized messenger RNA vaccines "show promise" in pancreatic cancer, Nature said. The type of mRNA vaccines put a stop to Covid-19, a technology that, however, was initially conceived to try to develop vaccines against cancer. "The work fits perfectly with the growing number of papers showing evidence of these treatments," one researcher said.